Is Zepbound FDA Approved for Weight Loss?

Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound is the brand-name tirzepatide injection approved by the FDA in November 2023 for chronic weight loss in adults with obesity or overweight conditions. This dual-action GLP-1 and GIP receptor agonist produced average weight loss of 21% in clinical trials, marking a significant advancement in pharmaceutical weight management. PlexusDx provides access to compounded tirzepatide through licensed 503A pharmacies, offering patients nationwide options for this breakthrough therapy.

What Is Zepbound and When Was It FDA Approved?

Zepbound is the FDA-approved brand name for tirzepatide, a once-weekly injectable medication designed to treat chronic weight management in adults. The FDA granted approval on November 8, 2023, following successful Phase 3 clinical trials that demonstrated its efficacy in producing sustained weight loss. Zepbound works by activating two hormone receptors—GLP-1 and GIP—which reduce hunger signals, increase satiety, and improve blood sugar control.

The approval pathway included extensive safety and effectiveness data from over 5,000 participants across multiple trials. Patients using Zepbound achieved weight reductions ranging from 15% to 22% of their baseline body weight over 68 weeks, depending on the dose and individual response. This dual-receptor mechanism distinguishes tirzepatide from single-action GLP-1 agonists like semaglutide, offering some patients enhanced metabolic benefits.

Clinical Trial Results: How Much Weight Can Zepbound Help You Lose?

Zepbound's pivotal SURMOUNT trials demonstrated substantial weight loss outcomes across patient populations. In the SURMOUNT-3 trial, patients on the highest dose achieved an average 22.2% weight reduction after 68 weeks, compared to 2.6% in the placebo group. These results were consistent across different body mass index categories and age groups, supporting its effectiveness across diverse patient demographics.

Beyond weight loss, Zepbound demonstrated improvements in cardiovascular risk factors, including reduced waist circumference, lower blood pressure, and improved lipid profiles in many participants. The medication maintained its effects over time, with sustained weight loss observed throughout the trial period. However, individual results vary based on genetics, lifestyle adherence, metabolism, and underlying hormonal pathways—factors that personalized genetic testing can help identify.

Zepbound vs. Compounded Tirzepatide: What's the Difference?

Both Zepbound and compounded tirzepatide contain identical active pharmaceutical ingredients and work through the same biological mechanisms. The key differences lie in manufacturing, regulatory oversight, distribution, and cost. Zepbound is manufactured by Eli Lilly under FDA oversight as a branded pharmaceutical product, while compounded tirzepatide is prepared by licensed 503A compounding pharmacies using FDA-approved raw ingredients.

PlexusDx offers compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan from licensed 503A pharmacies, with no insurance requirement and nationwide availability across all 50 states. This accessibility model removes many barriers patients face with branded Zepbound, including insurance coverage denials, prior authorization delays, and supply shortages. Both formats require a medical consultation and prescription, but compounded options often provide faster access and more flexible pricing structures tailored to individual patient needs.

Understanding Tirzepatide: How the Dual-Action Mechanism Works

Tirzepatide activates two distinct hormone receptors in the body: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The GLP-1 pathway signals fullness to the brain, slows stomach emptying, and regulates blood sugar levels after meals. The GIP pathway enhances insulin secretion in response to nutrients and improves metabolic efficiency, creating a synergistic effect that distinguishes tirzepatide from single-receptor medications.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Access, Eligibility, and Next Steps for Tirzepatide Treatment

Tirzepatide through PlexusDx is available to patients across all 50 states without requiring commercial insurance coverage. The medication is compounded by licensed 503A pharmacies and remains HSA and FSA eligible, providing patients with additional savings opportunities. PlexusDx requires a brief medical consultation through its telemedicine platform to confirm eligibility and establish a treatment plan personalized to your health history.

PlexusDx's tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) across all commitment tiers—your dose may need to go up as your body adjusts, but your price won't increase. Optional Precision Peptide Genetic Testing ($298) provides insights into your peptide-pathway genetics, mapping 14 pathways and 150+ genetic insights to optimize your long-term treatment strategy. Patients can begin with tirzepatide, oral tirzepatide, or explore combination options like GLP-Squared to identify the approach best suited to their genetics and lifestyle.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Zepbound the only FDA-approved tirzepatide medication for weight loss?

Zepbound is the FDA-approved branded tirzepatide injection, but tirzepatide as an active ingredient is also available through licensed 503A compounding pharmacies. PlexusDx offers compounded tirzepatide injections with identical active ingredient to Zepbound, starting at $249 per month, providing cost-effective nationwide access without insurance requirements.

How much weight loss should I expect from tirzepatide treatment?

Clinical trials show average weight loss of 15% to 22% of baseline body weight over 68 weeks on tirzepatide. Individual results vary significantly based on genetics, lifestyle adherence, diet quality, and exercise consistency. PlexusDx's Precision Peptide Genetic Test can identify your genetic predisposition to tirzepatide response by analyzing variants in GIPR and FTO, and MC4R genes.

How much does PlexusDx tirzepatide cost compared to Zepbound?

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) with flat pricing across all commitment tiers—no flat per-compound pricing increases. Most branded Zepbound prescriptions through insurance face high copays or prior authorization denials. PlexusDx serves all 50 states without insurance requirements and accepts HSA and FSA payments for maximum flexibility.

What are the common side effects of tirzepatide, and are they different from other GLP-1 medications?

Tirzepatide's most common side effects include nausea, vomiting, constipation, and diarrhea—particularly during dose escalation—which typically improve over time as your body adapts. Because tirzepatide activates two receptors rather than one, gastrointestinal side effects may be slightly more pronounced initially in some patients. Starting with a lower dose and gradual escalation, as recommended during PlexusDx treatment, minimizes these effects for most people.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes. PlexusDx's Precision Peptide Genetic Test analyzes your genetic variants in GIPR and FTO, and MC4R pathways to assess your individual tirzepatide responsiveness. Testing costs $298, helping PlexusDx clinicians optimize your treatment plan for maximum long-term success.

Related Reading

• Wegovy Vs Zepbound Weight Loss
• Zepbound For Weight Loss
• Maxlife Weight Loss
• Remedy Meds Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.